PEDIATRIX MEDICAL GROUP INC (MD) Stock Fundamental Analysis
NYSE:MD - New York Stock Exchange, Inc. - US58502B1061 - Common Stock - Currency: USD
Overall MD gets a fundamental rating of 5 out of 10. We evaluated MD against 103 industry peers in the Health Care Providers & Services industry. MD has an average financial health and profitability rating. MD scores decently on growth, while it is valued quite cheap. This could make an interesting combination.
1. Profitability
1.1 Basic Checks
MD had positive earnings in the past year.
MD had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: MD reported negative net income in multiple years.
In the past 5 years MD always reported a positive cash flow from operatings.
1.2 Ratios
With a Return On Assets value of -4.13%, MD is not doing good in the industry: 65.05% of the companies in the same industry are doing better.
MD has a Return On Equity of -10.44%. This is in the lower half of the industry: MD underperforms 61.16% of its industry peers.
The Return On Invested Capital of MD (9.08%) is better than 78.64% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for MD is in line with the industry average of 9.71%.
The last Return On Invested Capital (9.08%) for MD is above the 3 year average (7.83%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.13% | ||
| ROE | -10.44% | ||
| ROIC | 9.08% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
1.3 Margins
MD's Operating Margin of 10.02% is amongst the best of the industry. MD outperforms 80.58% of its industry peers.
MD's Operating Margin has declined in the last couple of years.
The Profit Margin and Gross Margin are not available for MD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.02% | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MD is creating some value.
Compared to 1 year ago, MD has more shares outstanding
The number of shares outstanding for MD has been increased compared to 5 years ago.
The debt/assets ratio for MD is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 1.85 indicates that MD is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of MD (1.85) is comparable to the rest of the industry.
MD has a debt to FCF ratio of 3.15. This is a good value and a sign of high solvency as MD would need 3.15 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.15, MD is in the better half of the industry, outperforming 75.73% of the companies in the same industry.
MD has a Debt/Equity ratio of 0.75. This is a neutral value indicating MD is somewhat dependend on debt financing.
The Debt to Equity ratio of MD (0.75) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.75 | ||
| Debt/FCF | 3.15 | ||
| Altman-Z | 1.85 |
ROIC/WACC1.08
WACC8.38%
2.3 Liquidity
A Current Ratio of 1.81 indicates that MD should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.81, MD is in the better half of the industry, outperforming 66.02% of the companies in the same industry.
MD has a Quick Ratio of 1.81. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
MD has a Quick ratio of 1.81. This is in the better half of the industry: MD outperforms 67.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.81 | ||
| Quick Ratio | 1.81 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 31.71% over the past year.
The earnings per share for MD have been decreasing by -15.01% on average. This is quite bad
MD shows a decrease in Revenue. In the last year, the revenue decreased by -1.13%.
MD shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.49% yearly.
EPS 1Y (TTM)31.71%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%65%
Revenue 1Y (TTM)-1.13%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-7.42%
3.2 Future
MD is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.39% yearly.
The Revenue is expected to grow by 2.24% on average over the next years.
EPS Next Y15.09%
EPS Next 2Y8.97%
EPS Next 3Y6.79%
EPS Next 5Y1.39%
Revenue Next Year-6.17%
Revenue Next 2Y-1.57%
Revenue Next 3Y0.53%
Revenue Next 5Y2.24%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 8.12, the valuation of MD can be described as very reasonable.
Based on the Price/Earnings ratio, MD is valued cheaply inside the industry as 96.12% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 27.52, MD is valued rather cheaply.
A Price/Forward Earnings ratio of 7.44 indicates a rather cheap valuation of MD.
Based on the Price/Forward Earnings ratio, MD is valued cheaply inside the industry as 96.12% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.58, MD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.12 | ||
| Fwd PE | 7.44 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MD is valued cheaper than 89.32% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, MD is valued cheaper than 92.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.82 | ||
| EV/EBITDA | 6.22 |
4.3 Compensation for Growth
MD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.54
PEG (5Y)N/A
EPS Next 2Y8.97%
EPS Next 3Y6.79%
5. Dividend
5.1 Amount
MD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
13.16
+0.04 (+0.3%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners91.66%
Inst Owner Change0%
Ins Owners1.89%
Ins Owner Change5.91%
Market Cap1.13B
Analysts78.75
Price Target17.49 (32.9%)
Short Float %2.58%
Short Ratio2.37
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.85%
Min EPS beat(2)32.73%
Max EPS beat(2)34.96%
EPS beat(4)4
Avg EPS beat(4)22.2%
Min EPS beat(4)5.21%
Max EPS beat(4)34.96%
EPS beat(8)5
Avg EPS beat(8)6.83%
EPS beat(12)5
Avg EPS beat(12)1.12%
EPS beat(16)9
Avg EPS beat(16)4.81%
Revenue beat(2)1
Avg Revenue beat(2)-0.56%
Min Revenue beat(2)-1.44%
Max Revenue beat(2)0.31%
Revenue beat(4)1
Avg Revenue beat(4)-1.2%
Min Revenue beat(4)-3.14%
Max Revenue beat(4)0.31%
Revenue beat(8)1
Avg Revenue beat(8)-2.7%
Revenue beat(12)1
Avg Revenue beat(12)-3.01%
Revenue beat(16)3
Avg Revenue beat(16)-2.21%
PT rev (1m)0%
PT rev (3m)-6.61%
EPS NQ rev (1m)-0.59%
EPS NQ rev (3m)2.35%
EPS NY rev (1m)2.23%
EPS NY rev (3m)7.97%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.53%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.12 | ||
| Fwd PE | 7.44 | ||
| P/S | 0.57 | ||
| P/FCF | 5.82 | ||
| P/OCF | 5.27 | ||
| P/B | 1.43 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.22 |
EPS(TTM)1.62
EY12.31%
EPS(NY)1.77
Fwd EY13.44%
FCF(TTM)2.26
FCFY17.19%
OCF(TTM)2.49
OCFY18.96%
SpS23
BVpS9.19
TBVpS-5.4
PEG (NY)0.54
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.13% | ||
| ROE | -10.44% | ||
| ROCE | 11.5% | ||
| ROIC | 9.08% | ||
| ROICexc | 10.41% | ||
| ROICexgc | 62.51% | ||
| OM | 10.02% | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | 9.83% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
ROICexc(3y)8.94%
ROICexc(5y)8.89%
ROICexgc(3y)78.23%
ROICexgc(5y)75.12%
ROCE(3y)9.91%
ROCE(5y)9.03%
ROICexcg growth 3Y26.95%
ROICexcg growth 5Y24.1%
ROICexc growth 3Y3.64%
ROICexc growth 5Y14.51%
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.99
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.75 | ||
| Debt/FCF | 3.15 | ||
| Debt/EBITDA | 2.62 | ||
| Cap/Depr | 73.43% | ||
| Cap/Sales | 1.01% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 95.15% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.81 | ||
| Quick Ratio | 1.81 | ||
| Altman-Z | 1.85 |
F-Score5
WACC8.38%
ROIC/WACC1.08
Cap/Depr(3y)81.28%
Cap/Depr(5y)89.11%
Cap/Sales(3y)1.42%
Cap/Sales(5y)1.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.71%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%65%
EPS Next Y15.09%
EPS Next 2Y8.97%
EPS Next 3Y6.79%
EPS Next 5Y1.39%
Revenue 1Y (TTM)-1.13%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-7.42%
Revenue Next Year-6.17%
Revenue Next 2Y-1.57%
Revenue Next 3Y0.53%
Revenue Next 5Y2.24%
EBIT growth 1Y30.12%
EBIT growth 3Y-5.51%
EBIT growth 5Y-4.62%
EBIT Next Year41.08%
EBIT Next 3Y15.15%
EBIT Next 5YN/A
FCF growth 1Y45.08%
FCF growth 3Y60.68%
FCF growth 5Y-11.42%
OCF growth 1Y31.09%
OCF growth 3Y39.11%
OCF growth 5Y-10.4%